



Special Track Session 4

Oncology & Theranostics Committee + Radiation Protection Committee

Sunday, October 5, 16:45 – 18:15

Session Title

Debate: Routes to Optimized Theranostics: Is Dosimetry Paving or Standing in the Way?

Moderators

Sigrid Svegborn (Malmö, Sweden)

Clément Bailly (Nantes, France)

Point of view: Do we need Dosimetry for Optimization of Theranostics?/ Pro

Marta Cremonesi (Milan, Italy)

Point of view: Do we need Dosimetry for Optimization of Theranostics?/ Con

Christophe Deroose (Leuven, Belgium)

Educational Objectives

1. To provide insights in the implementation of Dosimetry for Targeted Radionuclide Therapy
2. To explain the accessibility of clinical dosimetry
3. To become familiar with the latest EANM guidelines developments

Summary

Clinical dosimetry is increasingly used in Theranostics domain. To understand how dosimetry may guide us through the targeted radionuclide therapy journey, it is essential to become familiar with some essential aspects. This debate session offers the platform to openly discuss with experts about the latest developments on therapeutic strategies regarding new radiopharmaceuticals, supported by clinical evidence.

Key Words

Targeted Radionuclide Therapy; Oncology; Dosimetry